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Almost all humans are latently IgG-seropositive 
for the double-stranded DNA human herpesvirus 5 
named cytomegalovirus (CMV). CMV is an AIDS-
defining World Health Organization (WHO) stage 4 
opportunistic infection for both adults and children, 
seen when the CD4 T-cell count falls below 100 
cells/µl and as an immune reconstitution syndrome 
after starting highly active antiretroviral therapy 
(HAART).1 
CLINICAL MANIFESTATIONS
Active CMV disease may present multi-systemically, 
with significant morbidity and mortality. Organ sys-
tem manifestations include:
CMV retinitis (CMV-R). This is a visual emergency 
usually presenting with blurred vision, floaters, black 
spots, flashing lights, distortions, redness and photo-
phobia, but sometimes asymptomatic. WHO clini-
cal diagnosis guidelines for CMV-R include dilated 
pupil indirect fundoscopic identification of ‘discrete 
patches of retinal whitening with distinct borders, 
spreading centrifugally, often following blood ves-
sels, associated with retinal vasculitis, haemorrhage 
and necrosis’.2 Figs 1 and 2 show CMV-R before and 
after local treatment, respectively. This fundoscopic 
picture is known as the ‘pizza pie’ appearance. CMV-
R may result in blindness.3 
CMV of the gastro-intestinal tract. Colitis is symp-
tomatic as chronic watery diarrhoea that may become 
bloody, and oesophagitis symptomatic as dysphagia, 
anorexia and weight loss. Hepatitis may occur, and 
there are reports of acalculous cholecystitis.
CMV adrenalitis. Adrenal insufficiency may manifest 
as postural hypotension, fatigue, hyponatraemia, 
hyperkalaemia and acidosis. It has a high mortality 
rate.4
CMV pneumonitis. Manifestations are tachypnoea, 
hypoxia and dry cough, which are commonly misdi-
agnosed as Pneumocystis jirovecii pneumonia.5
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Cytomegalovirus is a multi-systemic infection reactivated in the immunocompromised. Diagnosis and treat-
ment are prohibitively costly in sub-Saharan Africa, and efforts need to be made for their price reduction 
to support the expanding highly active antiretroviral treatment programme in the region.
Fig. 1. CMV Retinitis at baseline. Full-thickness retinal 
necrosis along the inferotemporal arcade with some 
haemorrhage. There is minimal vitritis and mild macular 
oedema (courtesy Dr Linda Visser, University of KwaZulu-
Natal).
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CMV of the neurological system.6 Encephalitis pres-
ents with headache, subacute personality changes, 
decreased concentration, and progressive dementia. 
Transverse myelitis may occur. CMV is a recognised 
cause of acute inflammatory demyelinating polyra-
diculopathy (Guillain-Barré syndrome), the hallmarks 
of which are rapidly progressive ascending and often 
asymmetrical paraesthesiae, sensory loss and areflex-
ia, as well as urinary retention, constipation and in-
continence. The cerebrospinal fluid may demonstrate 
polymorphonucleocytosis and raised protein, and the 
diagnostic method of choice is polymerase chain re-
action (PCR) testing of the cerebrospinal fluid for 
CMV DNA.
SOUTH AFRICAN SPECTRUM OF DISEASE
Most data for CMV in the developed world were 
established in the 1990s, before the HAART era. 
CMV-R was found in a third of AIDS patients, with 
a large resulting burden of blindness.7 In one pre-
HAART Swiss study of 48 patients, median survival 
after CMV retinitis was 6 months.8 HAART improved 
survival markedly in AIDS CMV-R patients.9
There is a paucity of CMV data in the developing 
world. CMV has been called the ‘neglected disease of 
the AIDS pandemic’ because of poor diagnostic and 
treatment capability.1 In South Africa’s pre-HAART 
era, 90 AIDS patients were treated for CMV-R at the 
University of Natal over 7 years, and the incidence 
was noted to increase with time.10 A cross-sectional 
study screening all HIV-infected patients with CD4 
counts <50 cells/µl in Khayelitsha, South Africa, 
diagnosed CMV-R in 2% of these patients using 
dilated pupil indirect ophthalmoscopy.1 In a South 
African autopsy study of 47 HIV-infected cadavers 
where the clinician-attributed cause of death had 
been tuberculosis, CMV pneumonitis was proven in 
15% and 66% tested positive for CMV-DNA.11
South Africa has both a high burden of HIV disease12 
and a large, expanding HAART programme.13 Many 
South African HIV-infected patients present for ini-
tiation of HAART when the CD4 count is less than 
100 cells/µl,14 and often the median is less than 50 
cells/µl,15 which makes them susceptible to CMV dis-
ease. The return to health and longevity that HAART 
confers16 shapes a powerful argument to treat CMV 
efficiently and prevent its debilitating effects.
DIAGNOSTIC OPTIONS
A variety of testing options exist to identify active 
systemic CMV infection (Table I). Viral culture is tra-
ditionally accepted as the ‘gold standard’ method of 
detection.17 Simpler and more rapid options are now 
proving as or more effective.18 The pp65 antigen as-
say can provide very sensitive results in less than 6 
hours, the main drawback being the need for im-
mediate sample processing after retrieval in order to 
ensure test validity. Serological tests for the pres-
ence of IgM and IgG antibodies may have little di-
agnostic value in the immunocompromised patient. 
CMV DNA-PCR tests provide sensitive results that 
can reproducibly quantify CMV viral loads.19 In HIV-
infected patients, both DNA-PCR and pp65 antigen 
assay have proven to be more predictive in detect-
ing CMV than serology or viral culture.20 The CMV 
pp67 mRNA test is a promising new method used in 
research settings.
TREATMENT: THE URGENT NEED FOR 
VALGANCICLOVIR PRICE REDUCTION IN SA FOR 
CMV TREATMENT IN HIV PATIENTS
CMV treatment strategies (Table II) include systemic 
as well as local products, the latter for opthalmo-
logical indications. After completion of an induction 
phase, patients remain on maintenance therapy until 
immune recovery (CD4 >100 cells/µl).
Because southern African health facilities are poorly 
resourced, widespread use of intra-ocular ganciclovir 
(GCV) is not feasible.1 Specialist ophthalmological 
services are scarce in the state sector, and sometimes 
non-existent in rural areas. Intra-ocular GCV may not 
always be acceptable to patients, and is not with-
out procedure-related adverse effects such as end- 
ophthalmitis.10 Most importantly, intra-ocular GCV 
does not prevent spread of CMV to the other eye, and 
completely fails to treat disseminated CMV.1,10
Unfortunately, the exorbitant cost of systemic CMV 
treatments is prohibitive in the state sector. Systemic 
GCV necessitates a 3-week stay in hospital for in-
travenous induction, followed by oral maintenance 
GCV.21 Lengthy intravenous induction is not always 
realistic in resource-poor settings and may place 
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 Fig. 2. CMV retinitis after six intra-ocular ganciclovir 
injections. Note scarring in the area of previous necrosis. 
There is less vitritis, and the macular oedema has resolved. 
Haemorrhages may take months to resolve, and intraretinal 
gliosis can usually be seen late (courtesy Dr Linda Visser, 
University of KwaZulu-Natal).
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Test Tube/transport Samples Volume required Turnaround time Price estimate (2009)
pvt = estimated prices courtesy Toga Laboratories; state = estimated prices courtesy NHLS/NICD.
TABLE I. CMV DIAGNOSTIC TESTS
CMV viral culture 
(shell vial)
CMV pp65 antigen 
(IFA)




DNA-PCR (i.e. CMV 
viral load)
No preservative 
Send on ice to ar-




perature, must be 
received at NICD 
before 14h00 





Urine, CSF aspirate, 
breastmilk
Blood not an ideal 
sample
Whole blood  
Result may be 




ing blood, CSF, etc.
Whole blood
        1 ml
        5 ml
2 - 7 d (state), 
3 - 28 d (pvt)












Drug  Dose  Price estimates across sectors  Safety
   Private State NGO
Valganciclovir  
(Valcyte;  Roche) 
450 mg per tablet, 
60 tablets per bottle
No generics cur-




Inj.: 500 mg in 10 ml 
vials ×5
Caps: 250 mg (84), 
500 mg (90) 
No generics cur-











900 mg bd po 
with meals × 21 
days
900 mg/d po 
with meals until 
HAART restores 
CD4 count >100 
cells/µl
5 mg/kg IV bd × 
21 days
1 g tds po
R24 719.87
for 21 days
R17 657.05 per 
month
R2 558.24  for 
5 vials
R19 479.32 for 
21 days
R13 913.85 per 
month






















FBC every 2 days 
Reduce dose 
by 30 - 50% if 






with AZT or ddI: 
similar toxicities 
Oral ganciclovir is not available in South Africa
Suggest maintenance with valganciclovir
In a recumbent patient, 2 mg of a 25 mg/ml ganciclovir solution in normal saline 
is injected with a 1 ml syringe and 30G needle, 4 mm behind the limbus of the eye 
superiorly with the patient looking down. Patients are given intravitreal ganciclovir 
injections twice a week for the first 2 weeks, then weekly until immune recovery or 
retinitis quiescence9
*Minimum order of CHF 10 000. Each 60-tab box of 450 mg tablets costs CHF 500, plus freight and insurance changes apply (estimated CHF 177.40 + 40.20 respec-
tively for a 26-box order) (CHF = Swiss franc, 1 CHF = 7.47309 ZAR, exchange rate at 1 June 2009). NGO orders can be placed only at Roche Basle (sandra.torriani_
cazzato@roche.com). The lead time is 3 months after receipt of firm order. Prices quoted are per Roche, May/June 2009.
FBI = full blood count; AZT = zidovudine.
TABLE II. CMV TREATMENT IN ADULTS
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immune-compromised patients at risk of contracting 
nosocomial illnesses.
The benefits of valganciclovir are evident: it is taken 
orally, easy to administer in resource-poor settings, 
well tolerated, and efficacious in both induction and 
maintenance phases of treatment.21 Its cost currently 
prevents its use in South African CMV AIDS patients.
Second-line intravenous treatment options such as 
foscarnet and cidofovir are avoided because of neph-
ro-toxicity.
PAEDIATRIC CMV TREATMENT AND 
PREVENTION IN PREGNANCY
Congenital CMV causes a broad range of neurodevel-
opmental deficits in both symptomatic and initially 
asymptomatic neonates, including microcephaly, cho-
rioretinits and sensorineural hearing loss.
A 6-week course of intravenous ganciclovir has been 
shown to be effective in preventing hearing loss, im-
proving weight gain and head circumference, and 
resolving hepatic dysfunction, hepatomegaly and re-
tinitis. Ganciclovir toxicity, especially neutropenia, can 
however be life-threatening.22
Results of a small pharmacokinetic study show that 
oral valganciclovir at a dose of 16 mg/kg provided 
similar plasma levels of drug compared with 6 mg/kg 
intravenous ganciclovir, so it appears that valganci-
clovir is a promising option for treating neonatal and 
paediatric patients.23
Vertical CMV transmission is trans-placental, and the 
rate is observed to be higher in HIV-1-infected moth-
ers. Infants who are co-infected with HIV-1 and CMV 
are more likely to have rapid HIV disease progres-
sion.24
Valganciclovir and ganciclovir are both considered po-
tentially teratogenic from animal data, but there are 
no controlled studies in pregnant women.
A recent development in March 2009 is a CMV vac-
cine that may offer future public health benefits for 
pregnant women by eliminating congenital CMV.25
HOW CAN VALGANCICLOVIR PRICE REDUCTION 
BE ACHIEVED IN SOUTH AFRICA?
Currently, the cost of CMV treatment makes it unaf-
fordable to most.
Letters of concern on behalf of the South African HIV 
Clinicians Society have been sent to Roche urging price 
reduction of CMV treatments in the sub-Saharan Af-
rican region. Various organisations internationally are 
lobbying for price reduction, including Médecins Sans 
Frontières, Universities Allied for Essential Medicines 
and the Clinton HIV/AIDS Foundation.
Valganciclovir for CMV treatment in AIDS patients 
must be placed on our state tender request list. Cur-
rently it is available through state discretionary funds 
to transplant patients only. Government should con-
sider compulsory licensing for price-slashed generic 
production of valganciclovir for the state sector.
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